NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats

American Journal of Physiology - Cell Physiology

Volumn 301, Issue 2, 2011, Pages

  Lin, Nan ^a   Chen, Si ^a,b   Pan, Weidong ^a   Xu, Linan ^a   Hu, Kunpeng ^a   Xu, Ruiyun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Fibroblast growth factor 2; Smooth muscle actin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CYCLIN D1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; NP 603; PROTEIN P21; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

ACTINS; ANIMALS; CARBON TETRACHLORIDE; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; HEPATIC STELLATE CELLS; INDOLES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MAP KINASE KINASE 1; PHOSPHORYLATION; PROPIONIC ACIDS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TYROSINE;

RATTUS;

EID: 79960993665     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00452.2010     Document Type: Article

References (31)

1. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47: 677-685, 2008.
2. Ankoma-Sey V, Matli M, Chang KB, Lalazar A, Donner DB, Wong L, Warren RS, Friedman SL. Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 17: 115-121, 1998.
3. Aziz KA, Till KJ, Chen H, Slupsky JR, Campbell F, Cawley JC, Zuzel M. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood 102: 1051-1056, 2003.
4. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394, 2003.
5. Braun BS, Shannon K. The sum is greater than the FGFR1 partner. Cancer Cell 5: 203-204, 2004.
6. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta 1773: 1299-1310, 2007.
7. Charlotte F, Win KM, Preaux AM, Mavier P, Dhumeaux D, Zafrani ES, Rosenbaum J. Immunolocalization of heparin-binding growth factors (HBGF) types 1 and 2 in rat liver. Selective hyperexpression of HBGF-2 in carbon tetrachloride-induced fibrosis. J Pathol 169: 471-476, 1993.
8. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29: 976-985, 2007.
9. Chen A, Zhang L, Xu J, Tang J. The antioxidant (-)-epigallocatechin- 3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression. Biochem J 368: 695-704, 2002
10. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW, Kanzler S. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45: 419-428, 2006.
11. Fibbi G, Pucci M, Grappone C, Pellegrini G, Salzano R, Casini A, Milani S, Del RM. Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 29: 868-878, 1999.
12. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, Berger W. Fibroblast growth factor receptormediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7: 3408-3419, 2008.
13. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 19: 129-140, 1999.
14. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172, 2008.
15. Friedman SL. Liver fibrosis- rom bench to bedside. J Hepatol 38, Suppl 1: S38-S53, 2003.
16. Hartkamp J, Troppmair J, Rapp UR. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res 59: 2195-2202, 1999.
17. Ho PY, Hsu SP, Liang YC, Kuo ML, Ho YS, Lee WS. Inhibition of the ERK phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells. Toxicol Appl Pharmacol 229: 86-93, 2008.
18. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102: 538-549, 1998.
19. Kammasud N, Boonyarat C, Tsunoda S, Sakurai H, Saiki I, Grierson DS, Vajragupta O. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 17: 4812-4818, 2007.
20. Katoh M, Katoh M. FGF signaling network in the gastrointestinal tract (review). Int J Oncol 29: 163-168, 2006.
21. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23: 3501-3508, 2004.
22. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich Bunn PA BA,Jr, Heasley LE. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75: 196-207, 2009.
23. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137, 2005.
24. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia 12: 1013-1025, 1998.
25. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21: 397-416, 2001.
26. Rosenbaum J, Blazejewski S, Preaux AM, Mallat A, Dhumeaux D, Mavier P. Fibroblast growth factor 2 and transforming growth factor beta 1 interactions in human liver myofibroblasts. Gastroenterology 109: 1986-1996, 1995.
27. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 21: 351-372, 2001.
28. Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA. Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology 50: 1512-1523, 2009.
29. Steiling H, Wustefeld T, Bugnon P, Brauchle M, Fassler R, Teupser D, Thiery J, Gordon JI, Trautwein C, Werner S. Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration. Oncogene 22: 4380-4388, 2003.
30. Thisse B, Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 287: 390-402, 2005.
31. Yu C, Wang F, Jin C, Huang X, Miller DL, Basilico C, McKeehan WL. Role of fibroblast growth factor type 1 and 2 in carbon tetrachlorideinduced hepatic injury and fibrogenesis. Am J Pathol 163: 1653-1662, 2003.